Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry

Tsuyoshi Kaneko; Sameer Hirji; Syed Zaid; Rudiger Lange; Jörg Kempfert; Lenard Conradi; Christian Hagl; Michael A Borger; Maurizio Taramasso; Tom C Nguyen; Gorav Ailawadi; Ashish S Shah; Robert L Smith; Amedeo Anselmi; Matthew A Romano; Walid Ben Ali; Basel Ramlawi; Kendra J Grubb; Newell B Robinson; Luigi Pirelli; Michael W A Chu; Martin Andreas; Jean-Francois Obadia; Marco Gennari; Andrea Garatti; Didier Tchetche; Tamim M Nazif; Vinayak N Bapat; Thomas Modine; Paolo Denti; Gilbert H L Tang; CUTTING-EDGE Investigators

doi:10.1016/j.jcin.2021.07.029

Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry

Standard

Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry. / Kaneko, Tsuyoshi; Hirji, Sameer; Zaid, Syed; Lange, Rudiger; Kempfert, Jörg; Conradi, Lenard; Hagl, Christian; Borger, Michael A; Taramasso, Maurizio; Nguyen, Tom C; Ailawadi, Gorav; Shah, Ashish S; Smith, Robert L; Anselmi, Amedeo; Romano, Matthew A; Ben Ali, Walid; Ramlawi, Basel; Grubb, Kendra J; Robinson, Newell B; Pirelli, Luigi; Chu, Michael W A; Andreas, Martin; Obadia, Jean-Francois; Gennari, Marco; Garatti, Andrea; Tchetche, Didier; Nazif, Tamim M; Bapat, Vinayak N; Modine, Thomas; Denti, Paolo; Tang, Gilbert H L; CUTTING-EDGE Investigators.

in: JACC-CARDIOVASC INTE, Jahrgang 14, Nr. 18, 27.09.2021, S. 2010-2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kaneko, T, Hirji, S, Zaid, S, Lange, R, Kempfert, J, Conradi, L, Hagl, C, Borger, MA, Taramasso, M, Nguyen, TC, Ailawadi, G, Shah, AS, Smith, RL, Anselmi, A, Romano, MA, Ben Ali, W, Ramlawi, B, Grubb, KJ, Robinson, NB, Pirelli, L, Chu, MWA, Andreas, M, Obadia, J-F, Gennari, M, Garatti, A, Tchetche, D, Nazif, TM, Bapat, VN, Modine, T, Denti, P, Tang, GHL & CUTTING-EDGE Investigators 2021, 'Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry', JACC-CARDIOVASC INTE, Jg. 14, Nr. 18, S. 2010-2021. https://doi.org/10.1016/j.jcin.2021.07.029

APA

Kaneko, T., Hirji, S., Zaid, S., Lange, R., Kempfert, J., Conradi, L., Hagl, C., Borger, M. A., Taramasso, M., Nguyen, T. C., Ailawadi, G., Shah, A. S., Smith, R. L., Anselmi, A., Romano, M. A., Ben Ali, W., Ramlawi, B., Grubb, K. J., Robinson, N. B., ... CUTTING-EDGE Investigators (2021). Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry. JACC-CARDIOVASC INTE, 14(18), 2010-2021. https://doi.org/10.1016/j.jcin.2021.07.029

Vancouver

Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L et al. Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry. JACC-CARDIOVASC INTE. 2021 Sep 27;14(18):2010-2021. https://doi.org/10.1016/j.jcin.2021.07.029

Bibtex

@article{2c48f8524ab44817b7fcd0342456e016,

title = "Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry",

abstract = "OBJECTIVES: The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER).BACKGROUND: Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking.METHODS: Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year.RESULTS: From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery.CONCLUSIONS: In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.",

keywords = "Aged, Aged, 80 and over, Heart Valve Prosthesis Implantation/adverse effects, Humans, Middle Aged, Mitral Valve/diagnostic imaging, Mitral Valve Insufficiency/diagnostic imaging, Registries, Retrospective Studies, Treatment Outcome",

author = "Tsuyoshi Kaneko and Sameer Hirji and Syed Zaid and Rudiger Lange and J{\"o}rg Kempfert and Lenard Conradi and Christian Hagl and Borger, {Michael A} and Maurizio Taramasso and Nguyen, {Tom C} and Gorav Ailawadi and Shah, {Ashish S} and Smith, {Robert L} and Amedeo Anselmi and Romano, {Matthew A} and {Ben Ali}, Walid and Basel Ramlawi and Grubb, {Kendra J} and Robinson, {Newell B} and Luigi Pirelli and Chu, {Michael W A} and Martin Andreas and Jean-Francois Obadia and Marco Gennari and Andrea Garatti and Didier Tchetche and Nazif, {Tamim M} and Bapat, {Vinayak N} and Thomas Modine and Paolo Denti and Tang, {Gilbert H L} and {CUTTING-EDGE Investigators}",

year = "2021",

month = sep,

day = "27",

doi = "10.1016/j.jcin.2021.07.029",

language = "English",

volume = "14",

pages = "2010--2021",

journal = "JACC-CARDIOVASC INTE",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "18",

}

RIS

TY - JOUR

T1 - Mitral Valve Surgery After Transcatheter Edge-to-Edge Repair: Mid-Term Outcomes From the CUTTING-EDGE International Registry

AU - Kaneko, Tsuyoshi

AU - Hirji, Sameer

AU - Zaid, Syed

AU - Lange, Rudiger

AU - Kempfert, Jörg

AU - Conradi, Lenard

AU - Hagl, Christian

AU - Borger, Michael A

AU - Taramasso, Maurizio

AU - Nguyen, Tom C

AU - Ailawadi, Gorav

AU - Shah, Ashish S

AU - Smith, Robert L

AU - Anselmi, Amedeo

AU - Romano, Matthew A

AU - Ben Ali, Walid

AU - Ramlawi, Basel

AU - Grubb, Kendra J

AU - Robinson, Newell B

AU - Pirelli, Luigi

AU - Chu, Michael W A

AU - Andreas, Martin

AU - Obadia, Jean-Francois

AU - Gennari, Marco

AU - Garatti, Andrea

AU - Tchetche, Didier

AU - Nazif, Tamim M

AU - Bapat, Vinayak N

AU - Modine, Thomas

AU - Denti, Paolo

AU - Tang, Gilbert H L

AU - CUTTING-EDGE Investigators

PY - 2021/9/27

Y1 - 2021/9/27

N2 - OBJECTIVES: The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER).BACKGROUND: Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking.METHODS: Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year.RESULTS: From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery.CONCLUSIONS: In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.

AB - OBJECTIVES: The aim of this study was to determine clinical and echocardiographic characteristics, mechanisms of failure, and outcomes of mitral valve (MV) surgery after transcatheter edge-to-edge repair (TEER).BACKGROUND: Although >100,000 mitral TEER procedures have been performed worldwide, longitudinal data on MV surgery after TEER are lacking.METHODS: Data from the multicenter, international CUTTING-EDGE registry were retrospectively analyzed. Clinical and echocardiographic outcomes were evaluated. Median follow-up duration was 9.0 months (interquartile range [IQR]: 1.2-25.7 months) after MV surgery, and follow-up was 96.1% complete at 30 days and 81.1% complete at 1 year.RESULTS: From July 2009 to July 2020, 332 patients across 34 centers underwent MV surgery after TEER. The mean age was 73.8 ± 10.1 years, median Society of Thoracic Surgeons risk for MV repair at initial TEER was 4.0 (IQR: 2.3-7.3), and primary/mixed and secondary mitral regurgitation were present in 59.0% and 38.5%, respectively. The median interval from TEER to surgery was 3.5 months (IQR: 0.5-11.9 months), with overall median Society of Thoracic Surgeons risk of 4.8% for MV replacement (IQR: 2.8%-8.4%). The primary indication for surgery was recurrent mitral regurgitation (33.5%), and MV replacement and concomitant tricuspid surgery were performed in 92.5% and 42.2% of patients, respectively. The 30-day and 1-year mortality rates were 16.6% and 31.3%, respectively. On Kaplan-Meier analysis, the actuarial estimates of mortality were 24.1% at 1 year and 31.7% at 3 years after MV surgery.CONCLUSIONS: In this first report of the CUTTING-EDGE registry, the mortality and morbidity risks of MV surgery after TEER were not negligible, and only <10% of patients underwent MV repair. These registry data provide valuable insights for further research to improve these outcomes.

KW - Aged

KW - Aged, 80 and over

KW - Heart Valve Prosthesis Implantation/adverse effects

KW - Humans

KW - Middle Aged

KW - Mitral Valve/diagnostic imaging

KW - Mitral Valve Insufficiency/diagnostic imaging

KW - Registries

KW - Retrospective Studies

KW - Treatment Outcome

U2 - 10.1016/j.jcin.2021.07.029

DO - 10.1016/j.jcin.2021.07.029

M3 - SCORING: Journal article

C2 - 34556275

VL - 14

SP - 2010

EP - 2021

JO - JACC-CARDIOVASC INTE

JF - JACC-CARDIOVASC INTE

SN - 1936-8798

IS - 18

ER -